Compound Primer
What Is Tesamorelin? The GHRH Analog, Trial Evidence, and Sourcing
Updated · 3 cited sources · ResearchChem Research Team
Short answer: Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH), structurally identical to GHRH(1-44) except for a trans-3-hexenoyl group on the N-terminus that slows enzymatic degradation. The FDA approved tesamorelin (brand name Egrifta) in 2010 for one specific indication — reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — making it the only peptide of its class approved for a human indication. ResearchChem supplies tesamorelin as a research-use vial at 10 mg for $60.
What is tesamorelin?
Tesamorelin is a 44-amino-acid synthetic peptide: a modified version of the first 44 residues of endogenous human growth-hormone-releasing hormone (GHRH). The chemical modification is a trans-3-hexenoyl (TH9507) group attached to the N-terminal tyrosine, which slows breakdown by dipeptidyl peptidase-IV, the enzyme that normally inactivates native GHRH within minutes [1].
Because the molecule is structurally almost identical to endogenous GHRH, it acts at the pituitary GHRH receptor and raises pulsatile growth-hormone secretion and the downstream IGF-I response. That mechanism separates it from ghrelin-receptor agonists (ipamorelin, MK-677) and from short-acting GHRH fragments. For a mechanism-focused comparison of the GH-axis research peptides, see CJC-1295 vs ipamorelin.
Is tesamorelin approved?
Yes — but for one indication only. The U.S. Food and Drug Administration approved tesamorelin (brand name Egrifta) on November 10, 2010, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It was the first approval of a peptide in this class, and tesamorelin remains the only FDA-approved GHRH analog for a chronic indication as of 2026. Outside that specific labeled use, tesamorelin is handled as an investigational or research compound — including the research-use supply documented in this article.
What have the trials reported?
The trial results below are the FDA-registration data for the approved drug Egrifta (trade name of tesamorelin acetate). The ResearchChem vial is supplied for in-vitro and animal research only; no claim about its use in humans or in compounding is made.
Two multicenter, double-blind, placebo-controlled phase 3 trials formed the basis of the FDA approval. In the pivotal Falutz 2007 trial, 412 HIV-infected adults with excess abdominal fat were randomized to tesamorelin 2 mg daily or placebo for 26 weeks. The trial reported a −15.2% change in visceral adipose tissue (VAT) with tesamorelin versus +5.0% with placebo; abdominal subcutaneous adipose tissue and trunk-to-limb fat ratios also improved, as did IGF-I levels (+73%) [1].
A pooled analysis of the two phase 3 trials plus a 26-week safety extension (N=816) reported similar VAT reductions at 26 weeks (−15.4% vs +0.9% with placebo) and a maintained response at 52 weeks in patients who continued treatment; regression of some of the VAT reduction occurred when tesamorelin was withdrawn. Treatment-emergent adverse events most commonly included arthralgia, pain in extremity, peripheral edema, and hyperglycemia; the overall safety profile was described as consistent with the expected class effect of a GH-axis agent [2]. A 2021 NIH-funded secondary analysis in HIV-associated NAFLD used targeted proteomics to map tesamorelin response pathways in liver and plasma [3].
The research-use tesamorelin vial
- SKU: TESA-10. Size: 10 mg lyophilized powder, one vial.
- Price: $60 at /shop/tesamorelin.
- Compliance line on the 40×20 mm label: "RESEARCH USE ONLY · NOT FOR HUMAN USE".
- Storage: unopened at −20 °C; reconstitute per standard in-vitro lab practice.
- COA: the lot-specific Certificate of Analysis is sent on request — email [email protected] with the lot number from the vial.
Every order of $50 or more also receives one 100 mg GHK-Cu vial free (SKU GHKCU-100). See free GHK-Cu with any $50 order for the exact terms, and how to read a peptide COA for the fields a COA should carry.
Frequently asked questions
What does tesamorelin do mechanistically?
Tesamorelin binds the pituitary GHRH receptor and raises pulsatile growth-hormone secretion. The trans-3-hexenoyl modification slows degradation by dipeptidyl peptidase-IV, which otherwise inactivates native GHRH within minutes.
Is tesamorelin an FDA-approved drug?
Yes, for one indication. The FDA approved tesamorelin (Egrifta) in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. For every other use it is investigational or research-use only.
How is tesamorelin different from CJC-1295 or ipamorelin?
Tesamorelin is a near-full-length GHRH analog (44 amino acids). CJC-1295 is a modified GHRH(1-29) fragment with an albumin-binding linker that extends its half-life. Ipamorelin is a pentapeptide that acts at the ghrelin/GHS-R1a receptor, not the GHRH receptor.
What did the phase 3 trials report?
In the pivotal Falutz 2007 NEJM trial (N=412), tesamorelin 2 mg daily for 26 weeks produced a −15.2% change in visceral adipose tissue vs +5.0% with placebo, with +73% IGF-I. A pooled analysis of the two phase 3 trials reported a maintained response at 52 weeks; VAT regressed when tesamorelin was withdrawn.
How is tesamorelin stored?
Unopened tesamorelin is typically stored at −20 °C, then reconstituted with bacteriostatic water for in-vitro use. The lot-specific storage and handling details appear on every shipped label.
Cited studies
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV.. N Engl J Med. 357(23):2359-2370 (2007). PubMed 18057338 DOI
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.. J Clin Endocrinol Metab. 95(9):4291-4304 (2010). PubMed 20554713 DOI
- Fourman LT, Stanley TL, Billingsley JM, et al. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.. Sci Rep. 11(1):10485 (2021). PubMed 34006921 DOI
Related compounds
- Tesamorelin — GHRH Analog
- CJC-1295 + Ipamorelin — GH Peptide Stack
Keep reading
Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.